['asthma']
['budesonide/formoterol easyhaler 320/9 ug/inhalation 4 inh', 'budesonide/formoterol easyhaler 320/9 ug/inhalation 1 inh', 'symbicort turbuhaler 320/9 ug/inhalation 4 inh', 'symbicort turbuhaler 320/9 ug/inhalation 1inh', 'placebo symbicort turbuhaler 320/9 ug/inhalation 4 inh', 'placebo budesonide/formoterol easyhaler 320/9 ug/inhalation 4 inh', 'placebo budesonide/formoterol easyhaler 320/9 ug/inhalation 1 inh', 'placebo symbicort turbuhaler 320/9 ug/inhalation 1 inh']

        Main inclusion criteria:

          -  Written informed consent

          -  Asthma diagnosis for at least 6 months

          -  Prebronchodilator FEV1 45-90% of the predicted value

          -  Demonstration of reversible airway obstruction

          -  Stable asthma on the same regular treatment for at least 4 weeks before the study

          -  Non-smoker for at least 6 months before the study

        Main exclusion criteria

          -  Respiratory infection within 4 weeks before the study

          -  Smoking history of more than 10 pack-years

          -  Other severe chronic respiratory disease than asthma

          -  Concurrent illness that would interfere with the interpretation of the study results
             or constitute a health risk for the patient if he/she takes part in the study

          -  Corrected QT interval > 450 ms in males or > 470 ms in females

          -  Abnormal serum potassium value or other clinically significant laboratory finding

          -  Systolic blood pressure over 180 mmHg and/or diastolic blood pressure over 100 mmHg

          -  Treatment with a long-acting β2-agonist, a xanthine-derivative, a β-blocker or with a
             corticosteroid (other than inhaled) within 4 weeks before the study

          -  Use of drugs that prolong QT-interval

          -  Women who are pregnant, breast-feeding or without reliable contraception

          -  Participation in another clinical drug study
      